Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 770 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hb-SS Disease Clear all
Recruiting Phase 4 Interventional

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

NCT04657822
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 100 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Augusta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Terminated Phase 1Phase 2 Interventional

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

NCT04852172
View directory record Official record
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
L-citrulline, D5 1/2NS
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 1 Interventional

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

NCT04285827
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
CSL889
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 22, 2026, 4:29 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About Sickle Cell Disease In Adult Patients

NCT05407805
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Electronic Diary
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Upper Marlboro, Maryland • Waltham, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Recruiting Not applicable Interventional

Virtual Reality for SCD VOC

NCT07674277
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Sham 2D Headset Control, Passive Immersive 3D Virtual Reality, Active Immersive Interactive 3D Virtual Reality
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

NCT03715972
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions
Hydroxyurea, Acetazolamide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions

NCT02731157
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Rejuvesol, Blood transfusion
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease

NCT01771731
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cannabis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 22, 2026, 4:29 AM EDT
Terminated No phase listed Observational Results available

Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

NCT04930445
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oxbryta® (voxelotor) 500mg Tablets
Drug
Lead sponsor
Pfizer
Industry
Eligibility
4 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
43
States / cities
Mobile, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

NCT04255875
View directory record Official record
Conditions
Healthy, Sickle Cell Anemia
Interventions
Placebo, PF-07209326
Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
16
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Active, not recruiting Phase 2 Interventional

Stroke Prevention With Hydroxyurea Enabled Through Research and Education (SPHERE)

NCT03948867
View directory record Official record
Conditions
Sickle Cell Anemia in Children
Interventions
Hydroxyurea, Elevated Arm TCD Examination, Normal Arm TCD Examination
Drug · Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 16 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

NCT03593395
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Peer Mentoring [PM], Structured Education Based Transition Program STE
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Mobile, Alabama • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 22, 2026, 4:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

RH Genotype Matched RBC Transfusions

NCT04156893
View directory record Official record
Conditions
Sickle Cells Disease
Interventions
Red cell units that are genotype matched at the RHD and RHCE loci
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Completed No phase listed Observational

Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease

NCT01959958
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Questionnaire/Interview
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 22, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

NCT05583721
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
[13N]NH3, Lexiscan, Positron emission tomography
Drug · Diagnostic Test
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional

Codeine in Sickle Cell Disease

NCT00174538
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Codeine (30 mg)
Drug
Lead sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Shared-Decision Making for Hydroxyurea

NCT03442114
View directory record Official record
Conditions
Sickle Cell Anemia, Children, Only
Interventions
Hydroxyurea SDM Toolkit, Clinician Pocket Guide
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 5 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 22, 2026, 4:29 AM EDT
Not listed Phase 2 Interventional

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

NCT00408447
View directory record Official record
Conditions
Sickle Cell Disease, Beta Thalassemia
Interventions
Busulfan, Fludarabine, Alemtuzumab, Allogeneic stem cell transplant
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
1 Month to 30 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 22, 2026, 4:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases

NCT00840567
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Skin biopsy, Blood draw & sample
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 22, 2026, 4:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease

NCT00451919
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Not applicable Interventional

Sickle Cell, Pain and Mediterranean Diet

NCT06886477
View directory record Official record
Conditions
Sickle Cell, Sickle Cell Disease, Sickle Cell Disease Without Crisis, Mediterranean Diet
Interventions
Mediterranean Diet, Usual Diet
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

NCT00236093
View directory record Official record
Conditions
Pain, Cancer, Sickle Cell Anemia, Severe Burns
Interventions
ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
26
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

NCT01119833
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Interventions
GMI-1070, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
12 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 22, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Pain Management in Children and Young Adults With Sickle Cell Disease

NCT01954927
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 20 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 22, 2026, 4:29 AM EDT